Conference Correspondent

Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.

By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.

Leslie Lauersdorf discusses her perceptions regarding daratumumab therapy and identifies how her patients have benefited from this treatment option.
Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy.
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects.
Leslie Lauersdorf has seen the Janssen CarePath Program help alleviate some of the financial burden of treatment for her patients.
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.
An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma.
Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma.
Page 9 of 28
Results 81 - 90 of 273